A Randomized, Placebo-controlled Crossover Study to Assess the Safety of Administering a Second Dose of a COVID-19 mRNA Vaccine in Individuals Who Experienced a Systemic Allergic Reaction to an Initial Dose

Condition:   Systemic Allergic Reaction Interventions:   Biological: Pfizer-BioNTech COVID-19 Vaccine;   Other: Placebo Sponsor:   National Institute of Allergy and Infectious Diseases (NIAID) Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials